Discovery and Validation of Nitroxoline as a Novel STAT3 Inhibitor in Drug-resistant Urothelial Bladder Cancer

Repeated cycles of first-line chemotherapy drugs such as doxorubicin (DOX) and cisplatin (CIS) trigger frequent chemoresistance in recurrent urothelial bladder cancer (UBC). Nitroxoline (NTX), an antibiotic to treat urinary tract infections, has been recently repurposed for cancer treatment. Here we...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Wenfeng, Sun, Jingkai, Sadahira, Takuya, Xu, Naijin, Wada, Koichiro, Liu, Chunxiao, Araki, Motoo, Xu, Abai, Watanabe, Masami, Nasu, Yasutomo, Huang, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375225/
https://www.ncbi.nlm.nih.gov/pubmed/34421363
http://dx.doi.org/10.7150/ijbs.63125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375225/
https://www.ncbi.nlm.nih.gov/pubmed/34421363
http://dx.doi.org/10.7150/ijbs.63125

Ejemplares similares